Literature DB >> 21272053

Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Marcus A Björnsson1, Ulrika S H Simonsson.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Modelling has been used to describe the pain relief and dropout for a few non-steroidal anti-inflammatory drugs. WHAT THIS STUDY ADDS: • This study shows the relationship between dose, plasma concentration, pain intensity and dropout for naproxen and naproxcinod. It also extends previous models by using a visual analogue scale for pain intensity instead of modelling pain relief on a categorical scale, and shows the value of including informative dropout in the simulations for visual predictive checks. AIMS: To describe pain intensity (PI) measured on a visual analogue scale (VAS) and dropout due to request for rescue medication after administration of naproxcinod, naproxen or placebo in 242 patients after wisdom tooth removal. METHODS Non-linear mixed effects modelling was used to describe the plasma concentrations of naproxen, either formed from naproxcinod or from naproxen itself, and their relationship to PI and dropout. Goodness of fit was assessed by simultaneous simulations of PI and dropout.
RESULTS: Baseline PI for the typical patient was 52.7 mm. The PI was influenced by placebo effects, using an exponential model, and by naproxen concentrations using a sigmoid E(max) model. Typical maximal placebo effect was a decrease in PI by 20.2%, with an onset rate constant of 0.237 h(-1). EC(50) was 0.135 µmol l(-1). A Weibull time-to-event model was used for the dropout, where the hazard was dependent on the predicted PI and by the PI at baseline. Since the dropout was not at random, it was necessary to include the simulated dropout in visual predictive checks (VPC) of PI.
CONCLUSIONS: This model describes the relationship between drug effects, PI and the likelihood of dropout after naproxcinod, naproxen and placebo administration. The model provides an opportunity to describe the effects of other doses or formulations, after dental extraction. VPC created by simultaneous simulations of PI and dropout provides a good way of assessing the goodness of fit when there is informative dropout.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272053      PMCID: PMC3099376          DOI: 10.1111/j.1365-2125.2011.03924.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

3.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

Authors:  L E Friberg; R de Greef; T Kerbusch; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2009-04-22       Impact factor: 6.875

5.  Nonlinear plasma level response to high doses of naproxen.

Authors:  R Runkel; E Forchielli; H Sevelius; M Chaplin; E Segre
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

6.  Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.

Authors:  R Runkel; M Chaplin; G Boost; E Segre; E Forchielli
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

7.  Population pharmacodynamic model for ketorolac analgesia.

Authors:  J W Mandema; D R Stanski
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

8.  Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.

Authors:  Shashank Rohatagi; Helen Kastrissios; Kunihiro Sasahara; Kenneth Truitt; James B Moberly; Russell Wada; Daniel E Salazar
Journal:  Br J Clin Pharmacol       Date:  2008-06-03       Impact factor: 4.335

9.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

10.  Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.

Authors:  Jon Karlsson; Aldina Pivodic; Diana Aguirre; Thomas J Schnitzer
Journal:  J Rheumatol       Date:  2009-05-01       Impact factor: 4.666

View more
  8 in total

1.  Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

2.  Application of a hazard-based visual predictive check to evaluate parametric hazard models.

Authors:  Yeamin Huh; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-13       Impact factor: 2.745

3.  Performance of nonlinear mixed effects models in the presence of informative dropout.

Authors:  Marcus A Björnsson; Lena E Friberg; Ulrika S H Simonsson
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

4.  Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches.

Authors:  Rasmus Vestergaard Juul; Joakim Nyberg; Mads Kreilgaard; Lona Louring Christrup; Ulrika S H Simonsson; Trine Meldgaard Lund
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-07       Impact factor: 2.745

5.  A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain.

Authors:  Rasmus Vestergaard Juul; Joakim Nyberg; Trine Meldgaard Lund; Sten Rasmussen; Mads Kreilgaard; Lona Louring Christrup; Ulrika S H Simonsson
Journal:  Pharm Res       Date:  2016-01-11       Impact factor: 4.200

6.  A Model-Based Approach for Joint Analysis of Pain Intensity and Opioid Consumption in Postoperative Pain.

Authors:  Rasmus V Juul; Katrine R Knøsgaard; Anne E Olesen; Katja V Pedersen; Mads Kreilgaard; Lona L Christrup; Palle J Osther; Asbjørn M Drewes; Trine M Lund
Journal:  AAPS J       Date:  2016-04-26       Impact factor: 4.009

7.  Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

Authors:  T H T Nguyen; M-S Mouksassi; N Holford; N Al-Huniti; I Freedman; A C Hooker; J John; M O Karlsson; D R Mould; J J Pérez Ruixo; E L Plan; R Savic; J G C van Hasselt; B Weber; C Zhou; E Comets; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-02-10

8.  Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application.

Authors:  Rob C Van Wijk; Ulrika S H Simonsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.